Evidence map›Paper›PMID 26910116›Full record

ArticleOncotarget2016

Tumor size is an independent risk predictor for metachronous colorectal cancer.

Takaharu Kato, Sergio Alonso, Yuta Muto, Manuel Perucho, Toshiki Rikiyama

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Takaharu KatoDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Omiya-ku, Saitama, Japan.
Sergio AlonsoInstitute of Predictive and Personalized Medicine of Cancer (IMPPC), Institut d'Investigació en Ciéncies de la Salut Germans Trias I Pujol, (IGTP), Badalona, Barcelona, Spain.
Yuta MutoDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Omiya-ku, Saitama, Japan.
Manuel PeruchoInstitute of Predictive and Personalized Medicine of Cancer (IMPPC), Institut d'Investigació en Ciéncies de la Salut Germans Trias I Pujol, (IGTP), Badalona, Barcelona, Spain.
Toshiki RikiyamaDepartment of Surgery, Saitama Medical Center, Jichi Medical University, Omiya-ku, Saitama, Japan.
Institute of Predictive and Personalized Medicine of Cancer · ESJichi Medical University · JPJichi Medical University Saitama Medical Center · JPSanford Burnham Prebys Medical Discovery Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-hereditary colorectal cancer (CRC) patients are at higher risk of developing independent metachronous CRC than cancer-naïve individuals, but the reason is unknown. We studied metachronous CRC risk factors among one thousand five Japanese CRC patients who underwent surgery for CRC. Relative hazard risk of clinical and pathological features was assessed by univariate and multivariate Cox's proportional hazard regression analysis. Observed metachronous CRC incidence was also compared with the expected cancer incidence of the general population in Japan. Twenty-seven metachronous CRCs developed in 24 patients (2.4%) during a follow-up period of 3,676 person-years. Multivariate analysis revealed two factors associated with a high metachronous CRC risk: synchronous CRC (HR = 6.13; p = 1.3x10(-4)) and tumor size ≥ 6.5 cm (HR = 4.34; p = 1x10(-3)). Patients with either synchronous or large solitary tumors exhibited a higher risk for metachronous CRC than patients with solitary small tumors (HR = 7.3; p = 4.3x10(-6)) and that the general Japanese population (SIR = 7.01; p = 3.5x10(-9)), while patients with solitary small tumors did not (SIR = 1.07; p = 0.8). If patients younger than 60 years were excluded, the observations remained unchanged, with tumor size becoming stronger predictor (HR = 5.67; p = 1.7x10(-4)) than the presence of synchronous CRC (HR = 5.34; p = 9.6x10(-4)). Our novel finding that primary tumor size is a strong independent risk factor for metachronous CRC increases the sensitivity of prediction more than twice the presence of synchronous CRC. Our data provides new insights to assess the risk for metachronous lesions that should improve the surveillance regimen for CRC.

Indexed as

AgedColorectal NeoplasmsFemaleHumansMaleNeoplasms, Second PrimaryNeoplasm StagingRetrospective StudiesRisk Factorscolorectal cancermetachronous colorectal cancermultiple colorectal cancerssynchronous colorectal cancertumor size

Identifiers

PMID26910116
PMCPMC4951258
OpenAlexW2283799187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.